N-Benzoylstaurosporine (PKC412) inhibits Akt kinase inducing apoptosis in multiple myeloma cells

REFERENCES

• Hallek M, Bergsagel P, Anderson K. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998;91:3–21.
   Google Scholar
• Anderson K, Kyle R, Berenson J, Dalton W. Recent advances in the biology and treatment of multiple myeloma. Washing-ton, DC: American Society of Haematology Education Program; 1998. pp. 63–88.
   Google Scholar
• Sonneveld P, Lokhorst H, Vossebeld P. Drug resistance in multiple myeloma. Semin Haematol 1997;34:34–39.
   PubMed Web of Science ®Google Scholar
• Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe 0, Tanaka H. Autocrine generation and requirement of BSF-2/IL-6 for human multi-ple myelomas. Nature 1988;332: 83–85.
   Google Scholar
• Jourdan M, De Vos J, Mechti N, B Klein. Regulation of Bc1-2 family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha, and insulin-like growth factor 1. Cell Death Different 2000;7:1244–1252.
   PubMed Web of Science ®Google Scholar
• Klein B, Zhang X, Lu Z, Bataille R Interleukin-6 in human multiple myeloma. Blood 1995;85:863–872.
   PubMed Web of Science ®Google Scholar
• Podar K, Tai YT, Davies F, Lentzsch S, Sattler M, Hideshima T, Lin B, Gupta D, Shima Y, Chauhan D, Mitsiades C, Raje N, Richardson P, Anderson K. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 2001;98:428–435.
   PubMed Web of Science ®Google Scholar
• Tu Y, Renner S, Xu F, Fleishman A, Taylor J, Weisz J, Vescio R, Rettig M, Berenson J, Krajewski S, Reed J, Lichtenstein A. Bc1-xl_ expression in multiple myeloma: possible indicator of chemoresistance. Cancer Res 1998;58:256–262.
   PubMed Web of Science ®Google Scholar
• Zhang B, Gojo I, Fenton R Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 200299:1885-1893.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Nakamura N, Chauhan D, Anderson K. Biologic sequelae of interleukin-6 induced P13-K/Akt signal-ing in multiple myeloma. Oncogene 2001 20:5991–6000.
   PubMed Web of Science ®Google Scholar
• Ogata A, Chauhan D, Teoh G, Treon S, Urashima M, Schlossman R, Anderson K. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol 1997;159: 2212–2221.
   Google Scholar
• Catlett-Falcone R, Landowski T, Oshiro M, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna J, Nunez G, Dalton W, Jove R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999;10: 105–115.
   Google Scholar
• Puthier D, Bataille R, Amiot M. IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/ MAP kinase pathway. Eur J Immunol 1999;29: 3945–3950.
   Google Scholar
• Mitsiades C, Mitsiades N, Poulaki V, Schlossman R, AkiyamaM, Chauhan D, Hideshima T, Treon S, Munshi N, Richardson P, Anderson K. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 2002;21: 5673–5683.
   Google Scholar
• Ge N, Rudikoff S. Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood 2000;96:2856–2861.
   PubMed Web of Science ®Google Scholar
• Hill M, Hemmings B. Inhibition of protein kinase B/Akt. Implications for cancer therapy. Pharmacol Therapeut 2002;93:243–251.
   PubMed Web of Science ®Google Scholar
• Cheng J, Ruggeri B, Klein W, Sonoda G, Altomare D, WatsonD, Testa J. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumourigenicity by antisense RNA. Proc Natl Acad Sci USA 1996;93: 3636–3641.
   Google Scholar
• Bellacosa A, De Feo D, Godwin A, Bell D, Cheng J, AltomareD, Wan M, Dubeau L, Scambia G, Masciullo V. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 1995;64: 280–285.
   Google Scholar
• Nakatani K, Thompson D, Barthel A, Sakaue H, Liu W, Weigel R, Roth R Up-regulation of Akt3 in oestrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 1999;274:21528–21532.
   PubMed Web of Science ®Google Scholar
• Ringshausen I, Schneller F, Bogner C, Hipp S, Duyster J, Peschel C, Decker T. Constitutively activated phosphatidyli-nositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase C delta. Blood 2002;100: 3741–3748.
   Google Scholar
• Hyun T, Yam A, Pece S, Xie X, Zhang J, Miki T, Gutkind J, Li W. Loss of PTEN expression leading to high Akt activation in human multiple myelomas. Blood 2000;96:3560–3568.
   PubMed Web of Science ®Google Scholar
• Hsu J, Shi Y, Krajewski S, Renner S, Fisher M, Reed J, Franke T, Lichtenstein A. The AKT kinase is activated in multiple myeloma tumour cells. Blood 2001;98:2853–2855.
   PubMed Web of Science ®Google Scholar
• Tu Y, Gardner A, Lichtenstein A. The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative re-sponses. Cancer Res 2000;60: 6763–6770.
   Google Scholar
• Choi Y, Zhang J, Murga C, Yu H, Koller E, Monia B, Gutkind J, Li W. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells. Oncogene 2002;21:5289–5300.
   PubMed Web of Science ®Google Scholar
• Shi Y, Gera J, Hu L, Bookstein R, Li W, Lichtenstein A. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res 2002;62:5027–5034.
   PubMed Web of Science ®Google Scholar
• Ge N, Rudikoff S. Expression of PTEN in PTEN-deficient multiple myeloma cells abolishes tumour growth in vivo. Oncogene 2000;19:4091–4095.
   PubMed Web of Science ®Google Scholar
• Hill M, Andjelkovic M, Brazil D, Ferrari S, Fabbro D, Hemmings B. Insulin-stimulated protein kinase B phosphor-ylation on Ser-473 is independent of its activity and occurs through a staurosporine-insensitive kinase. J Biol Chem 2001;276:25643–25646.
   PubMed Web of Science ®Google Scholar
• Tenzer A, Zingg D, Rocha S, Hemmings B, Fabbro D, Glanzmann C, Schubiger P, Bodis S, Pruschy M. The phosphatidylinositide 3?-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC41. Cancer Res 2001;61: 8203–8210.
   Google Scholar
• Fabbro D, Buchdunger E, Wood J, Mestan J, Hofmann F, Ferrari S, Mett H, O'Reilly T, Meyer T. Inhibitors of protein kinases: CGP41251, a protein kinase inhibitor with potential as an anticancer agent. Pharmacol Therapeut 1999;82: 293–301.
   Google Scholar
• Fabbro D, Ruetz S, Bodis S, Pruschy M, Csermark K, Man A, Campochiaro P, Wood J. O'Reilly T, Moyas T. PKC412 a protein kinase inhibitor with a broad therapeutic potential. Anti-Cancer Drug Design 2000;15: 17–28.
   Google Scholar
• Zaugg K, Rocha S, Resch H, Hegyi I, Oehler C, Glanzman C, Fabbro D, Bodis S, Pruschy M. Differential p53-dependent mechanism of radiosensitization in vitro and in vivo by the protein kinase C specific inhibitor PKC412. Cancer Res 2001;61: 732–738.
   Google Scholar
• Weisberg E, Boulton C, Kelly L, Monley P, Fabbro D, Meyer T, Gilliland G, Griffin J. Inhibition of mutant FLT3 receptorsin leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 2002;1:433–443.
   PubMed Web of Science ®Google Scholar
• Armstrong S, Kung A, Mabon M, Silverman L, Stam R, Den Boer M, Pieters R, Kersey J, Sallan S, Fletcher J, Golub T, Griffin J, Korsmeyer S. Inhibition of FLT3 in MLL: Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 2003;3: 173–183.
   Google Scholar
• Propper D, McDonald A, Man A, Thavasu P, Balkwill F, Braybrooke J, Caponigro F, Graf P, Dutreix C, Blackie R, Kaye S, Ganeson T, Talbot D, Hans A, Twelves C. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Chin Oncol 2001;19: 1485–1492.
   Google Scholar
• Grad J, Bahlis N, Reis I, Oshiro M, Dalton W, Boise L. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma. Blood 2001;98:805–813.
   PubMed Web of Science ®Google Scholar
• Greenstein S, Krett N, Kurosawa Y, Ma C, Chauhan D, Hideshima T, Anderson K, Rosen S. Characterization of the MI\4.1 human multiple myeloma (1v1I\4) cell lines: a model system to elucidate the characteristics, behaviour, and signal-ing of steroid-sensitive and -resistant MM cells. Exp Haematol 2003;31: 271–282.
   Google Scholar
• Zhang B, Fenton R Proliferation of IL-6-independent multi-ple myeloma does not require the activity of extracellular signal-regulated kinases (ERK1/2). J Cell Physiol 2002;193:42–54.
   PubMed Web of Science ®Google Scholar
• Coffer P, Woodgett J. Molecular cloning and characterization of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. Eur J Biochem 1991;201:475–481.
   PubMedGoogle Scholar
• Pene F, Claessens Y, Muller 0, Viguie F, Mayeux P, Dreyfus F, Lacombe C, Bouscary D. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P7056-kinase pathways in the pro-liferation and apoptosis in multiple myeloma. Oncogene 2002;21: 6587–6597.
   Google Scholar
• Shi Y, Hsu J, Hu L, Gera J, Lichtenstein A. Signal pathways involved in activation of p7056K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumour cells to interleukin-6. J Biol Chem 2002;277: 15712–15720.
   Google Scholar